Cabaletta Bio (CABA) Non-Current Deffered Revenue (2018 - 2019)
Cabaletta Bio (CABA) recorded quarterly Non-Current Deffered Revenue of $2.6 million in Q3 2019, up 1323.89% quarter-over-quarter from $180000.0 in Q4 2018.
Cabaletta Bio (CABA) Non-Current Deffered Revenue (2018 - 2019) Analysis & Trends
Cabaletta Bio's Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $2.6 million for Q3 2019.
- In Q3 2019, Non-Current Deffered Revenue changed N/A year-over-year to $2.6 million; the TTM figure through Sep 2019 stood at $2.6 million (changed N/A YoY), while the FY2018 annual figure was $180000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue was $2.6 million for Q3 2019 at Cabaletta Bio, up from $180000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $2.6 million in Q3 2019 to a low of $180000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cabaletta Bio | 151.84 Mn | 18.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 2.56 Mn |
| Dec 31, 2018 | 180,000.00 |